AHA 2014 Scientific Sessions: IMPROVE-IT Results Reported and What They Mean for the Future of ETC-1002

December 8, 2014
Tim Mayleben
President and Chief Executive Officer
Marianne Andreach
Vice President, Strategic Marketing and Product Planning

Last month, the American Heart Association (AHA) held its annual Scientific Sessions in Chicago, IL where presenters and attendees gathered from more than 105 countries to present cutting edge breakthroughs in cardiovascular science and research.  Esperion colleagues have attended and participated in Scientific Sessions for many years and always look forward to seeing and hearing… Read More

Equity Financing Now Complete: Moving ETC-1002 into Phase 3

October 31, 2014
Tim Mayleben
President and Chief Executive Officer

October was a very big month for our company!  Esperion not only announced positive top-line results from the ETC-1002-008 Phase 2b study in patients with hypercholesterolemia with or without statin intolerance, but within two weeks of this announcement we completed a successful follow-on public offering raising almost $100 million.  October proved to be an exciting,… Read More

Esperion Investor Day: Lighting the Way for Phase 2b Results

September 5, 2014
Tim Mayleben
President and Chief Executive Officer

On July 29th, Esperion held its inaugural investor day in New York City, with a tightly-packed agenda for the half-day event that included presentations from several of the world’s leading experts in their respective fields.  It was an exciting and informative day! Dr. James McKenney, President and CEO of National Clinical Research, and Professor Emeritus… Read More

Esperion’s Relocation Back to Ann Arbor

August 27, 2014

Esperion recently relocated back to its Ann Arbor roots!  Check out our newest video blog showcasing our colleagues hard at work, and the collaborative and innovative space we enjoy each day.  

Reflections One Year Post-IPO

June 26, 2014
Tim Mayleben
President and Chief Executive Officer

One year ago today the “new” Esperion re-entered the public markets with an initial public offering that raised $80 million and with a singular focus: to rapidly advance the development of ETC-1002, a unique, first-in-class, oral, once-daily low-density lipoprotein cholesterol (LDL-C) lowering therapy for patients with hypercholesterolemia who are unable to tolerate a statin. Since… Read More

Posted In: Company News

NLA 2014 Scientific Sessions: Placing the Focus on Statin Intolerance

May 19, 2014
Roger Newton, PhD, FAHA
Executive Chairman and Chief Scientific Officer
Marianne Andreach
Vice President, Strategic Marketing & Product Planning

As members of the Esperion team developing ETC-1002—a unique, first-in-class, orally available, once-daily small molecule designed to lower low density lipoprotein cholesterol (LDL-C) levels, particularly in individuals with hypercholesterolemia who are intolerant to statins—we are excited any time there is a specific emphasis on, or a new development in, this underserved patient population. In the… Read More